Application of kaura fir extract in preparation of product for resisting sepsis acute lung injury

Arachonone in the aqueous solution extract of Kauri ethanol can inhibit the occurrence and development of acute lung injury in sepsis, solve the problem of treatment of acute lung injury in sepsis, and provide a safe and low-toxic drug solution. It significantly improved survival rate and reduced lung tissue damage.

CN119015328AActive Publication Date: 2024-11-26PEKING UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202310584206.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-23
Publication Date
2024-11-26
Estimated Expiration
2043-05-23

AI Technical Summary

Technical Problem

There are currently no reports of the effects of kauri and its monomer components on sepsis-related, especially the lack of effective drug solutions in inhibiting acute lung injury in sepsis.

Method used

Using Kauri aqueous ethanol solution extract, containing Araucarone (AO) as the main active ingredient, inhibits the occurrence and development of acute lung injury in sepsis through oral routes, specifically manifested as inhibiting the polarization and inflammation of macrophages. Factor expression and oxidative stress relieve lung tissue damage.

Benefits of technology

Significantly inhibits acute lung injury in sepsis induced by LPS, improves survival rate, reduces lung mass index and inflammatory cell infiltration, and provides a safe and low-toxic anti-sepsis drug with strong pharmacological effects and richness. natural resource base.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004242681010000021
    Figure BDA0004242681010000021
  • Figure BDA0004242681010000061
    Figure BDA0004242681010000061
  • Figure FDA0004242681000000011
    Figure FDA0004242681000000011
Patent Text Reader

Abstract

The invention discloses an application of a kaura fir extract in preparation of a product for resisting sepsis acute lung injury, and belongs to the field of medicines. The invention discloses a new medicine application of a kaura extract (AD) and a monomer (Araucarone, AO) of the Araucarone, and particularly discloses a new medicine application of the Araucarone, the AD and the AO as well as a new medicine application of the Araucarone, the AD and the AO as well as a new medicine application of the Araucarone. The new application is the application of the kaura fir extract and the monomer Aucuconone in resisting acute lung injury caused by sepsis. The invention adopts a clinically related sepsis acute lung injury model, namely an LPS (Lipopolysaccharide)-induced mouse sepsis acute lung injury model; experiments prove that through intragastric administration of the kaura fir extract or the monomer Aucuconone, the LPS-induced acute lung injury of the sepsis in mice can be remarkably inhibited, and the kaura fir extract or the monomer Aucuconone can be used for preventing and treating the acute lung injury of the sepsis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of medicine, and in particular to application of a kauri pine extract in preparing a product for resisting sepsis-induced acute lung injury. Background Art

[0002] Kauri (Latin name Agathis dammara) is a tree that belongs to the gymnosperms, Pinaceae, Pinales, Araucariaceae, and Kauri genus. It is mainly distributed in tropical Asia and is introduced and cultivated in Xiamen and Fuzhou, my country. The volatile oil in its leaves mainly contains terpenoids, of which β-cuberene is the main component. In addition, it also contains alkanes, alcohols, ketones, and a small amount of aldehydes, ethers, and esters. It has important uses in medicine, spices, and daily chemicals, and is also of great significance in plant chemical taxonomy. The pharmacological effects of Kauri can be roughly divided into the following aspects: anti-tumor, antibacterial, anti-inflammatory, sedative, and antiasthmatic.

[0003] Sepsis is one of the representative diseases of acute systemic inflammatory diseases. Imbalance of inflammatory response is the most critical pathological basis of sepsis and runs through the whole process of sepsis. The acute response of the host to pathogens can cause polarization of macrophages M1, which will engulf pathogens and produce a large number of proinflammatory factors, eventually triggering a cytokine storm. The uncontrolled cytokine storm will eventually lead to shock, multiple organ failure and death. Inhibiting macrophage M1 polarization in the acute inflammatory phase of sepsis can inhibit the release of inflammatory factors, reduce tissue damage and improve survival rate. Therefore, regulating the homeostasis of macrophage polarization is of great significance to reduce tissue damage and mortality in patients with sepsis.

[0004] There are no reports on the effects of Kauri and its monomer components on sepsis. Summary of the invention

[0005] The purpose of the invention is to provide a new use of Kauri extract.

[0006] The new use of the Kauri cypress extract provided by the present invention is the use of the Kauri cypress extract in preparing products for preventing and / or treating sepsis-induced acute lung injury.

[0007] In the above application, the septic acute lung injury is septic acute lung injury caused by bacterial infection; specifically, the bacteria are Gram-negative bacteria.

[0008] More specifically, the septic acute lung injury is LPS-induced septic acute lung injury in mice.

[0009] The present invention also provides the use of the Kauri extract in at least one of the following:

[0010] 1) Application in the preparation of products for inhibiting acute lung injury caused by sepsis; specifically, the inhibition of acute lung injury caused by sepsis is specifically reflected in inhibiting the increase of lung weight index, alveolar interstitial remodeling and inflammatory cell infiltration;

[0011] 2) Application in the preparation of products for inhibiting inflammatory response in lung tissue; specifically, application in the preparation of products for inhibiting the expression of inflammatory factors in septic lung tissue; the inflammatory factor may specifically be at least one of IL-6, TNF-α, IL-18 and IL-1β;

[0012] 3) Application in the preparation of a product for inhibiting macrophage M1 polarization; specifically, the markers of macrophage M1 polarization are CD86, CD80 and iNOS;

[0013] 4) Application in the preparation of products for inhibiting the production of macrophage inflammatory factors; specifically, the macrophage inflammatory factors are IL-6, MCP-1 and TNF-α;

[0014] 5) Application in the preparation of a product for inhibiting oxidative stress in M1 polarized macrophages; specifically, the anti-oxidative stress protein in the M1 polarized macrophages is HO-1 protein;

[0015] 6) Application in the preparation of a product for inhibiting aerobic glycolysis of M1 polarized macrophages; specifically, the key enzyme of aerobic glycolysis of M1 polarized macrophages is hexokinase 2 (HK2), which inhibits glucose consumption and lactate production.

[0016] In the above application, the active ingredient of the Kauri extract includes Araucarone (AO), and its structural formula is as follows:

[0017]

[0018] In the above application, the Kauri extract is an ethanol aqueous solution extract of Kauri.

[0019] Specifically, the volume fraction of ethanol in the ethanol aqueous solution is 60% to 100%, and can be specifically 95%.

[0020] The Kauri extract of the present invention can be prepared according to the existing disclosed method.

[0021] For example, the preparation method can be referred to as follows: the rhizomes of Kauri pine are dried and crushed, then soaked in ethanol aqueous solution, heated to a slightly boiling state, subjected to reflux extraction, and the extract is collected, concentrated, and dried to obtain the Kauri pine extract.

[0022] The soaking time may be 1 hour; the reflux extraction is performed at least once, preferably 3 times; and the reflux extraction time each time is 1 to 2 hours.

[0023] In the above applications, the product is a medicine or a pharmaceutical preparation.

[0024] The drug can be introduced into the body such as muscle, intradermal, subcutaneous, intravenous, mucosal tissue by injection, oral administration, spraying, penetration, absorption, physical or chemical mediation; or introduced into the body after being mixed or wrapped with other substances.

[0025] When necessary, one or more pharmaceutically acceptable carriers may be added to the above-mentioned drugs to prepare pharmaceutical preparations. The carriers include conventional diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, lubricants, etc. in the pharmaceutical field.

[0026] The drug can be prepared into various forms such as injection, suspension, powder, tablet, granule, etc. The drugs in various dosage forms can be prepared according to conventional methods in the pharmaceutical field.

[0027] The present invention adopts a clinically relevant model of acute lung injury caused by sepsis: LPS-induced acute lung injury caused by sepsis in mice. Experiments have shown that oral administration of Kauri extract can significantly inhibit the occurrence and development of LPS-induced acute lung injury caused by sepsis in mice. At the same time, it has been shown that the active ingredients in the Kauri extract include Araucarone (AO).

[0028] The drug for preventing acute lung injury caused by sepsis provided by the present invention is safe, low-toxic, and has a strong pharmacological effect; its raw material source is abundant and can be extracted from kauri plants. The present invention provides a new drug source for preventing, protecting, treating and studying acute lung injury caused by sepsis, and is easy to promote and apply, and can generate huge social and economic benefits in a relatively short period of time. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 The extract of Kauri (AD) inhibited LPS-induced M1 polarization, inflammatory factor production and oxidative stress in RAW264.7 macrophages;

[0030] Figure 1 a in the figure is the MTT experiment to detect the safety of AD cells; Figure 1 bd in the table indicates that AD inhibits the increase in mRNA expression levels of inflammatory factors IL-6, TNF-α, and MCP-1; Figure 1 eg in which AD inhibits the increase in the mRNA expression levels of M1 polarized macrophage markers CD86, CD80, and iNOS; Figure 1hi in the figure indicates that AD inhibits the upregulation of protein expression of iNOS, a marker of M1 polarization; Figure 1 jl in the figure indicates that AD inhibits the up-regulation of protein expression of inflammatory factors caspase 1 and IL-18; Figure 1 m in the figure is detected by DCFHDA probe. AD inhibits the increase of oxidative stress level in RAW264.7 macrophages induced by LPS.

[0031] Figure 2 The extract of Kauri (AD) inhibited LPS-induced M1 polarization of bone marrow-derived macrophages (BMDM) and the production of inflammatory factors;

[0032] Figure 2 a, b, f, and g in the figure respectively indicate that AD inhibits the increase of mRNA expression levels of inflammatory factors TNF-α, MCP-1, IL-6, and IL-18 in BMDM; Figure 2 ce in the table indicates that AD inhibited the increase in mRNA expression levels of iNOS, CD86, and CD80, markers of M1 polarized macrophages; Figure 2 i and h in the figure respectively indicate that AD inhibits the up-regulation of protein expression of iNOS, a marker of M1 polarization; Figure 2 jk in the figure indicates that AD inhibits the up-regulation of the expression of CD86, a marker of M1 polarization;

[0033] Figure 2 In ah, the concentration of AD was 25 μg / mL; Figure 2 In j and k, AD indicates treatment with 25 μg / mL AD; LPS indicates treatment with 100 ng / mL LPS; 0, 5, and 25 indicate treatment with 100 ng / mL LPS and different concentrations (μg / mL) of AD at the same time.

[0034] Figure 3 The extract of Kauri (AD) inhibited glycolysis in RAW264.7 cells and the expression of HK2 gene, a key enzyme in the glycolysis pathway;

[0035] Figure 3 ab in the figure indicates that AD inhibits the increase of glucose consumption and lactate production after 12 h of LPS treatment; Figure 3 cd in the figure indicates that AD inhibited the increase of glucose consumption and lactate production after 24 h of LPS treatment; Figure 3 e in the figure shows that AD inhibited the increase in mRNA expression level of hexokinase (HK2) in RAW264.7 cells induced by LPS.

[0036] Figure 4 The extract of Kauri (AD) inhibited glycolysis in BMDM cells and the expression of HK2 gene, a key enzyme in the glycolysis pathway;

[0037] Figure 4ab in the figure indicates that AD inhibits the increase of glucose consumption and lactate production after 12 h of LPS treatment; Figure 4 c in the figure shows that AD inhibits the increase in mRNA expression level of hexokinase (HK2) in BMDM induced by LPS.

[0038] Figure 5 The extract of Kauri (AD) inhibited acute lung injury, M1 polarized macrophage infiltration in lung tissue, and production of inflammatory factors in lung tissue in mice with sepsis.

[0039] Figure 5 ab in the figure is the improvement effect of 100 mg / kg AD on the survival rate of septic mice induced by intraperitoneal injection of 45 mg / kg LPS. Wherein, a is a flowchart of the mouse survival rate experiment; b is a statistical chart of the mouse survival rate; Figure 5 ck in the figure is the inhibitory effect of 100 mg / kg AD gavage on acute lung injury induced by 20 mg / kg LPS intraperitoneal injection in septic mice. Among them, c is a schematic diagram of the experimental process; d is AD inhibiting the increase of lung weight index induced by LPS in septic mice; ef is AD inhibiting the increase of mRNA expression levels of M1 polarization markers CD80 and CD86 in lung tissue of septic mice induced by LPS; gj are AD inhibiting the increase of mRNA expression levels of inflammatory factors IL-6, IL-18, TNF-α, and IL-1β in lung tissue; k is AD inhibiting LPS-induced mouse lung tissue injury (HE staining of lung tissue sections), including inhibiting alveolar septum thickening and cell infiltration.

[0040] Figure 6 Araucaria sinensis (AO) inhibits LPS-induced M1 polarization, inflammatory factor production and oxidative stress in RAW264.7 macrophages;

[0041] Figure 6 a in the figure is the effect of different concentrations of AO on cell survival rate detected by MTT experiment, and LPS is 100 ng / mL; Figure 6 bd in which 25 μM AO (with 25 μg / mL AD as control) inhibited the increase in mRNA expression levels of cellular inflammatory factors MCP-1, IL-6 and TNF-α induced by LPS (100 ng / mL); Figure 6 e in the figure indicates that 25 μM AO (with 25 μg / mL AD as control) inhibited the increase in the mRNA expression level of iNOS, a marker of M1 polarized macrophages, induced by LPS (100 ng / mL); Figure 6 fg in the figure indicate that different concentrations of AO (μM) inhibited the increase of mRNA expression levels of M1 polarized macrophage markers CD80 and CD86 induced by LPS (100 ng / mL); Figure 6The hj in which 25 μM AO (with 25 μg / mL AD as control) inhibited the down-regulation of antioxidant protein HO-1 protein expression level and the up-regulation of inflammatory factor IL-18 protein expression level induced by LPS (100 ng / mL).

[0042] Figure 7 Araucaria officinalis (AO) inhibits acute lung injury, M1 polarized macrophage infiltration in lung tissue, and production of inflammatory factors in lung tissue in septic mice;

[0043] Figure 7 The ah in the figure is the inhibitory effect of 100 mg / kg AO oral administration on acute lung injury induced by 20 mg / kg LPS intraperitoneal injection in septic mice. Among them, a is a schematic diagram of the experimental process; b is AO inhibiting the increase of lung weight index induced by LPS in septic mice; cd is AO inhibiting the increase of mRNA expression levels of M1 polarization markers CD80 and CD86 in lung tissues of septic mice induced by LPS; eg is AO inhibiting the increase of mRNA expression levels of inflammatory factors IL-6, TNF-α, and IL-1β in lung tissues of septic mice; h is HE staining of lung tissue sections of septic mice, indicating that AO can inhibit LPS-induced lung tissue damage in septic mice, including inhibiting alveolar septum thickening and inflammatory cell infiltration. DETAILED DESCRIPTION

[0044] The present invention is further described in detail below in conjunction with specific embodiments. The given examples are only for illustrating the present invention, rather than for limiting the scope of the present invention.

[0045] The experimental methods in the following examples are all conventional methods unless otherwise specified.

[0046] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0047] The percentages described in the following examples are all mass percentages, unless otherwise stated.

[0048] The lipopolysaccharide (LPS) used in the following examples was purchased from Sigma Aldrich, catalog number L2880.

[0049] In the following examples, the solvent of AD or AO is 0.5% sodium carboxymethyl cellulose, and the solvent of sodium carboxymethyl cellulose is distilled water;

[0050] The solvent for LPS is physiological saline.

[0051] Example 1. Preparation of Kauri Extract (AD) and Its Monomers

[0052] 1. Preparation of Kauri Extract

[0053] Dried and crushed Kauri root powder (367g) was placed in a 3.0L round-bottom flask, and 2.5L of 95% (v / v) ethanol was added to soak for 1h, then heated to a slightly boiling state, heated under reflux for 2h, and the extract was filtered while hot. The residue was then extracted with 2.0L of 95% (v / v) ethanol under reflux for 2 times, each time for 1.5h. The filtrates were combined, concentrated by rotary evaporator, vacuum dried, and weighed to obtain 105.3g of Kauri extract (extraction rate: 28.7%).

[0054] 2. Preparation of Monomers

[0055] Take the Kauri extract (100.0 g) prepared above, add 1.0 L of water to suspend it, extract it with dichloromethane, use 1.0 L of extractant each time, extract it 3 times, combine the extracts, and obtain 34.0 g of dichloromethane layer extract.

[0056] The dichloromethane layer extract (34 g) was mixed with silica gel (Qingdao Ocean Chemical, 300-400 mesh column chromatography silica gel; item number: 2.003447F6) at a mass ratio of 1:2, and purified by silica gel column chromatography with a column volume of 3.3 L. Gradient elution was performed with dichloromethane and dichloromethane / methanol in sequence. The elution gradient was pure dichloromethane, dichloromethane / methanol 50:1, 20:1, 10:1, 5:1, 2:1, 1:1, pure methanol (v / v), and each gradient was 6 L. Subsequently, the same components were combined according to the results of thin layer chromatography to obtain a total of 22 fractions. The No. 1 fraction (4.4 g) was mixed into 7.0 g of silica gel, loaded onto a silica gel column (column volume 261 mL), and eluted with petroleum ether and petroleum ether / ethyl acetate, respectively. The elution gradient was petroleum ether (600 mL), petroleum ether / ethyl acetate (v / v) 30:1, 20:1, 10:1, 5:1, 4:1, 3:1, 2:1, 1:1 (400 mL for each gradient). The same fractions were combined by thin layer chromatography to obtain 9 sub-fractions (A to I). Sub-fraction H was recrystallized at room temperature to obtain the monomer compound.

[0057] The purity of the monomer was tested by HPLC, and the purity was > 95%. The testing conditions were as follows:

[0058] Mobile phase: acetonitrile 100%; flow rate: 1 mL / min; chromatographic column: Welch Ultimate XB-C18 (250 mm×4.6 mm id, 5 μm); column temperature: 40° C.; detection wavelength: 254 nm, 210 nm.

[0059] The structure of the compound was identified by mass spectrometry and nuclear magnetic resonance spectroscopy.

[0060] Compound 1, ESI-MS m / z 301[M+H]+, 1H-NMR (CDCl3, 600MHz) δH: 5.50 (1H, m), 4.40 (2H, s), 3.26 (1H, br.s), 2.70 (1H, td, J=14.6, 5.3Hz ),2.29(1H,br.d,J=11.5Hz),2.27(1H,dt,J=14.7,3.8Hz),2.14(1H,m),2.12(1H,m),2.10(1H,m),1.94(1H,m ),1.75(1H,br.dd,J=6.2,3.1Hz),1.73(1H,m),1.68(1H,m),1.63(1H,td,J=12.8,3.7Hz),1.56(1H,dd,J=12. 2,4.1Hz),1.50(1H,td,J=13.9,4.0Hz),1.45(1H,qd,J=12.5,4.2Hz),1.14(3H,s),1.10(6H,s),1.07(3H,s);

[0061] 13C-NMR (CDCl3, 151MHz) δC: 216.5, 214.9, 133.3, 123.3, 64.1, 51.5, 50.7, 4 7.4,45.9,41.7,38.0,35.3,34.6,32.5,25.6,23.9,22.6,19.5,18.9,14.8.

[0062] The compound is named AO (Araucarone), and its structural formula is as follows:

[0063]

[0064] Example 2: Pharmacodynamics test of Kauri extract

[0065] 1. Experimental Materials

[0066] 1.1 Experimental animals

[0067] The mice used in the experiment were 8-week-old male C57BL / 6J mice with an average weight of 20-25 g, purchased from the Experimental Animal Center of Peking University Health Science Center. The principles of laboratory animal care (NIH publication number 85-23, revised edition 1996) were followed, and the experimental protocol was approved by the Animal Ethics Committee of Peking University Health Science Center (approval number: LA2021045): all mice were housed under 12-h light-dark cycle conditions with free access to food and water.

[0068] 1.2 Animal feed

[0069] The animals were maintained on a commercially available rodent diet.

[0070] 2. In vivo experimental methods

[0071] 2.1 LPS-induced sepsis acute lung injury model in mice

[0072] Eight-week-old male C57BL / 6J mice were injected intraperitoneally with 20 mg / kg LPS (LPS was prepared with saline to a concentration of 2 mg / mL) to induce acute lung injury in mice, and samples were collected 24 hours later. The control group was injected intraperitoneally with an equal amount of saline.

[0073] Eight-week-old male C57BL / 6J mice were injected intraperitoneally with 45 mg / kg of LPS (LPS was prepared with saline to a concentration of 5 mg / mL) to induce sepsis in mice, and the survival rate of mice was observed. The control group was injected intraperitoneally with an equal amount of saline.

[0074] 2.2 Pharmacological effects of Kauri extract against acute lung injury caused by sepsis

[0075] (1) Efficacy experiment

[0076] Eight-week-old male C57BL / 6J mice were randomly divided into a control group (6 mice), an LPS modeling group (6 mice), an LPS modeling group and a Kauri extract administration group (AD 100 mg / kg / day, 6 mice), or an LPS modeling group and a monomer administration group (AO 100 mg / kg / day, 6 mice). First, the mice were pre-gavaged for 5 days, and the control group and the LPS modeling group were gavaged with the same volume of solvent (0.5% sodium carboxymethyl cellulose) as the experimental group every day. The LPS modeling group and the Kauri extract administration group and the LPS modeling group and the monomer administration group were gavaged with 100 mg / kg of AD and AO every day (AD or AO was prepared into a suspension with a concentration of 12.5 mg / mL for administration). 2 hours after gavage on the 5th day, the control group was intraperitoneally injected with an equal amount of normal saline; the LPS modeling group, the LPS modeling group and the Kauri extract administration group, and the LPS modeling group and the monomer administration group were intraperitoneally injected with 20 mg / kg LPS. The mice were sacrificed 24 hours later, and serum and lung tissues were collected. After the LPS intraperitoneal injection model was established, no drug treatment was performed, and this LPS dose was a non-lethal dose, with a survival rate of 100% within 24 hours.

[0077] (2) Survival rate experiment

[0078] Eight-week-old male C57BL / 6J mice were randomly divided into a control group (6 mice), an LPS modeling group (6 mice), and an LPS modeling and kauri extract gavage group (gavage of AD 100 mg / kg / day, 6 mice). For the experiment of observing the survival rate, AD pretreatment was first performed for 5 days, and the control group and the LPS modeling group were gavaged with the same dose of solvent (0.5% sodium carboxymethyl cellulose) as the experimental group every day. The LPS modeling and kauri extract administration group was gavaged with AD 100 mg / kg every day. 2h after administration on the 5th day, the control group was intraperitoneally injected with an equal amount of normal saline; the LPS modeling group and the LPS modeling and kauri extract administration group were intraperitoneally injected with 45 mg / kg LPS. After that, the survival time of the mice was observed and the survival rate was plotted. No drug treatment was performed after LPS modeling. The mice in this group were no longer tested for lung weight index or RNA. When gavage, AD was prepared into a suspension with a concentration of 12.5 mg / mL for administration.

[0079] 2.3 Animal handling

[0080] 2.3.1 Collection of mouse serum

[0081] 24 hours after modeling, about 800 μL of blood was collected from the inner canthus of the anesthetized mice before sacrificing them, and the blood was temporarily stored at 37°C and centrifuged at 4000 rpm at room temperature for 30 min. The upper serum was collected and frozen in a -30°C refrigerator for later use.

[0082] 2.3.2 Mouse sampling

[0083] Lung tissue sampling: Weigh the mice and record the weight. After bleeding from the inner canthus, sacrifice the mice and fix them in a dissecting dish (plastic foam box) with a pin. Cut the mouse skin and subcutaneous membrane to expose the internal organs. Remove the lung tissue, vacuum remove the blood in the lung tissue in a cold PBS solution, weigh the lung tissue, retain the morphology of the left lung, fix it with paraformaldehyde, and then transfer it to 20% sucrose (w / v). After the lung tissue is sectioned, HE staining is performed to observe tissue damage. The right lung is frozen in a -80℃ refrigerator for later use.

[0084] 2.4 RNA extraction

[0085] (1) After taking out the right lung tissue from the -80℃ freezer, add 1 mL of total RNA extraction reagent (Trizol) for every 30 mg of tissue and homogenize, and let it stand on ice for 5 min. (For cells, add 1 mL of Trizol directly into the six-well plate, pipette and then aspirate into the EP tube).

[0086] (2) Add 200 μL of chloroform, shake vigorously for 30 seconds, and place on ice for 3 minutes.

[0087] (3) Centrifuge at 13,000 rpm for 15 min at 4°C.

[0088] (4) Take the supernatant (500 μL), add 500 μL of pre-cooled isopropanol, mix by inversion for 5 seconds, and let stand on ice for 10 minutes.

[0089] (5) Centrifuge at 13,000 rpm for 10 min at 4°C.

[0090] (6) Discard the supernatant and add 1 mL of pre-cooled 75% (v / v) ethanol (prepared with DEPC water) to wash the precipitate.

[0091] (7) Centrifuge at 4°C, 13,000 rpm for 10 min. Wash once more and repeat (6) (7).

[0092] (8) Dry the RNA at room temperature.

[0093] (9) Dissolve the RNA in an appropriate amount of diethyl pyrocarbonate (DEPC) water and use NanoDrop TM The concentration and quality were determined by a micro-UV-visible spectrophotometer. RNA samples were stored at -80℃.

[0094] 2.5 HE staining of lung tissue

[0095] (1) After the frozen sections were dried, they were washed with distilled water for 5 min × 3 times.

[0096] (2) Stain with hematoxylin stain for 5 minutes.

[0097] (3) Wash with distilled water and differentiate with 1% hydrochloric acid-ethanol (hydrochloric acid / anhydrous ethanol = 1:99, v / v) for a few seconds.

[0098] (4) Rinse with running water until the cell nuclei are clearly stained and the staining turns blue.

[0099] (5) Wash with 95% (v / v) ethanol for 2 min.

[0100] (6) Eosin staining for 30 min.

[0101] (7) Wash briefly with distilled water, then with 70% ethanol, 80% ethanol, and 90% ethanol for 30 seconds each, 95% ethanol for 5 minutes, and anhydrous ethanol for 5 minutes × 2 times; the above ethanol concentrations are all in volume percentage.

[0102] (8) Xylene 10 min × 2 times.

[0103] (9) Seal the slides with neutral gum, dry them, and then take photos.

[0104] 3. In vitro experimental methods

[0105] 3.1 Extraction of primary mouse bone marrow-derived macrophages

[0106] (1) Prepare 8-week-old C57BL / 6J mice with an average body weight of 20 to 22 g.

[0107] (2) The mice were anesthetized and killed, and sterile surgical instruments were used throughout the procedure. The mouse skin was disinfected with 75% (v / v) alcohol, and the skin was cut open at the base of the hind legs. The mouse skin was peeled off all the way to the feet to fully expose the muscles.

[0108] (3) Cut off the hind limbs and remove the skin using sterile scissors and forceps.

[0109] (4) Use scissors and forceps to remove the muscles adhered to the bones.

[0110] (5) Place the femur and tibia in a culture dish, disinfect with 75% (v / v) alcohol for 1 min, and then wash with PBS.

[0111] (6) After the bone marrow was isolated from the mouse tibia and femur, the cells were filtered using a 70 μm cell sieve to remove cell clumps, bones, hair, etc.

[0112] (7) Centrifuge the collected bone marrow cell suspension at 4°C, 450 g, for 10 min.

[0113] (8) Discard the supernatant, add erythrocyte lysis buffer (0.5 mL / cell), incubate on ice for 5 min to lyse erythrocytes. 4°C, 450 g, 10 min.

[0114] (9) Discard the supernatant and add Roswell Park Memorial Institute 1640 (RPMI 1640) complete medium to wash once. 4°C, 450g, 10 min.

[0115] (10) Discard the supernatant, resuspend the cells in 20 mL of prewarmed complete culture medium, transfer the cells to two 10 cm culture dishes, and culture at 37°C for 4 h.

[0116] (11) Collect the supernatant and discard the adherent cells (the adherent cells should be tissue-resident macrophages). Incubate at 4°C, 450 g, 10 min. Discard the supernatant and resuspend the cells in 10 mL of RPMI 1640 complete medium (containing 10% FBS and double antibody) containing 15% L929 cell supernatant (L929 supernatant: complete medium = 15:85, v / v).

[0117] (12) Add 20 mL of culture medium containing 15% L929 cell supernatant. Inoculate 10 mL / dish into a 10 cm dish and culture in a 37°C incubator for 7 days.

[0118] L929 cell supernatant: L929 cells were cultured in RPMI 1640 medium. On the second day after subculturing, the original medium was aspirated and non-adherent cells were washed away. Then 20 mL of RPMI 1640 complete medium was added and cultured for 7 consecutive days. After 7 days, the culture supernatant was aspirated and centrifuged at 600g and 4°C for 10 min. The precipitate was discarded and the supernatant was frozen in a -80°C refrigerator for later use.

[0119] 3.2 Establishment of in vitro M1 polarization model of bone marrow-derived macrophages and RAW264.7 macrophage cell line

[0120] (1) One million primary mouse bone marrow-derived macrophages (BMDM) (or RAW264.7 macrophages) were seeded into a 6-well plate at 4% density and 1 mL of RPMI 1640 complete medium (or DMEM complete medium) was added and cultured until adherence.

[0121] (2) The medium was replaced with 1 mL of serum-free RPMI 1640 medium (or DMEM medium) for starvation for 12 h, and then replaced with RPMI 1640 complete medium (or DMEM complete medium) containing 100 ng / mL LPS (LPS was prepared with sterile water to a concentration of 100 μg / mL for administration) for stimulation for 6 h (for RNA extraction) / 12 h (for protein extraction); the experimental group was given drug incubation at the same time, AD or AO was dissolved in dimethyl sulfoxide (DMSO) and prepared into a mother solution with a concentration of 25 mg / mL and 25 mmol / L for administration, respectively, and the control group and model group were given the same volume of DMSO. Each group was incubated in an incubator at 37°C, relative humidity 90%, and CO2 concentration 5% (v / v).

[0122] (3) Remove the culture medium from the cells, wash the cells three times with PBS, and add 1 mL of Trizol to each well for RNA extraction or 50 μL of protein lysis buffer for protein extraction and Western blot.

[0123] 3.3MTT experiment

[0124] (1) Collect RAW264.7 cells in the logarithmic growth phase.

[0125] (2) Adjust the concentration of the cell suspension: In a clean bench, clean the cell counting plate and cover glass with alcohol, take 20 μL of the cell suspension, and use the tip of the gun to press against the middle of one side of the cover glass and inject it into the counting plate. Under a low-power microscope, count the cells in the four large squares at the four corners and calculate the average value. The cell concentration in the suspension is: average value × 10 4The number of cells seeded in each well of a 96-well plate is 1×10 4 Add 100 μL to each well and adjust the concentration of the cell suspension with complete culture medium.

[0126] (3) Grouping according to experimental requirements: zero adjustment group (without cells), control group, and drug administration group (with 6 parallel wells).

[0127] (4) The 96-well plate was incubated in a 37°C incubator (relative humidity 90%, 5% CO2 concentration v / v) until the cells covered the bottom of the wells. After starvation for 12 hours with blank DMEM medium (without FBS), it was replaced with complete DMEM medium (containing 10% FBS, v / v) containing 100 ng / mL LPS (LPS was prepared with sterile water to a concentration of 100 μg / mL stock solution for administration) and incubated for another 12 hours. At the same time, a gradient of drug concentrations (AD or AO) was added to the drug administration group. AD or AO was prepared with DMSO to a concentration of 25 mg / mL and 25 mmol / L solution for administration.

[0128] (5) Terminate the culture, discard the culture medium, add 20 μL of 5.0 g / L 3-2,5-diphenyl-2-H-tetrazolium bromide (MTT) solution to each well, and culture in a 37°C cell culture incubator for another 4 h.

[0129] (6) After 4 hours, remove the supernatant. Add 150 μL of DMSO to each well and place in a microplate reader. Vibrate the plate for 10 minutes to allow the blue crystalline formazan to completely dissolve. Then measure the absorbance at a wavelength of 540 nm and calculate the cell survival rate according to the following formula:

[0130] Cell survival rate = (drug group - zero adjustment group) / (control group - zero adjustment group)

[0131] 3.4 Pharmacological effects of Kauri extract (AD) and monomeric AO on inhibiting RAW264.7 macrophages and BMDM M1 polarization, inflammatory factors and oxidative stress

[0132] RAW264.7 macrophages (or BMDM) were seeded in six-well plates at a density of 0.5 × 10 6 / mL, cultured with DMEM (or RPMI 1640) containing 10% FBS until adherence, and starved with serum-free DMEM (or RPMI 1640) for 12h. RAW264.7 macrophages (or BMDM) were cultured with complete DMEM (or RPMI1640) (containing 10% FBS) containing 100ng / mL LPS (LPS was prepared with sterile water to a concentration of 100μg / mL for administration), and the drug-treated group was simultaneously given 25μg / mL Kauri extract AD or 25μmol / L AO for incubation at 37℃, relative humidity 90%, and 5% CO2 v / v in an incubator. After 6h (for RNA extraction) / 12h (for protein extraction), cells were collected for detection of M1 polarization markers, inflammation, and oxidative stress markers. Six parallel wells were set up in each group. AD or AO was prepared with DMSO to a concentration of 25mg / mL and 25mmol / L solution for administration.

[0133] 3.5 Pharmacological effect of Kauri extract (AD) on inhibiting glycolysis in RAW264.7 macrophages and BMDM

[0134] RAW264.7 macrophages (or BMDM) were seeded in six-well plates at a density of 0.5 × 10 6 / mL, cultured with complete medium containing 10% FBS (RAW264.7 cells use DMEM, BMDM use RPMI 1640) until adherence, and starved cells with serum-free DMEM (or RPMI 1640) for 12h. RAW264.7 macrophages (or BMDM) were cultured with complete DMEM medium (or RPMI 1640 medium) (containing 10% FBS) containing 100ng / mL LPS (LPS was prepared with sterile water to a concentration of 100μg / mL for administration), and the drug-treated group was given 25μg / mL of Kauri extract AD at the same time, and incubated in an incubator at 37℃, relative humidity 90%, and 5% CO2 v / v. After 6h of culture, RNA was extracted to observe the expression of glycolysis key gene HK2, and the supernatant of the culture medium was aspirated for 12h or 24h to observe glucose consumption and lactic acid production. Six parallel wells were set up in each group. AD was prepared with DMSO to a concentration of 25mg / mL for administration.

[0135] 4. Experimental results and discussion

[0136] 4.1 Kauri extract (AD) inhibits LPS-induced M1 polarization, inflammation, and oxidative stress in RAW 264.7 macrophages

[0137] The cells were stimulated with 100 ng / mL LPS and treated with 25 μg / mL AD. The results showed that AD significantly inhibited the increase in mRNA expression levels of inflammatory factors IL-6, MCP-1, and TNF-α induced by LPS; inhibited the increase in mRNA expression levels of M1 polarization markers CD80, CD86, and iNOS and the upregulation of iNOS protein expression; AD inhibited the upregulation of protein expression of inflammatory factors caspase 1 and IL-18; AD inhibited the increase in ROS levels in cells induced by LPS (see Figure 1 ).

[0138] 4.2 Kauri extract (AD) inhibits LPS-induced M1 polarization and expression of inflammatory factors in BMDM

[0139] The cells were stimulated with 100 ng / mL LPS and treated with 25 μg / mL AD. The results showed that AD significantly inhibited the increase in mRNA expression levels of inflammatory factors IL-6, MCP-1, TNF-α and IL-18 induced by LPS; inhibited the increase in mRNA expression levels of M1 polarization markers CD80, CD86 and iNOS and the upregulation of iNOS protein expression; PE-labeled CD86 antibody flow cytometry detection showed that AD significantly inhibited the expression of M1 polarization marker CD86 in BMDM induced by LPS (see 2).

[0140] 4.3. Kauri extract (AD) inhibits glycolysis in RAW264.7 cells and regulates gene expression in the glucose metabolism pathway

[0141] The cells were stimulated with 100 ng / mL LPS and treated with 25 μg / mL AD. The results showed that AD significantly inhibited the increase of LPS-induced cell glycolysis after 12 h or 24 h of culture, reflecting the inhibition of glucose consumption and lactate production. At the same time, AD significantly inhibited the upregulation of mRNA expression of HK2, a key enzyme in glycolysis, induced by LPS (see Figure 3 ).

[0142] 4.4. Kauri extract (AD) inhibits glycolysis in BMDM cells and regulates gene expression in the glucose metabolism pathway

[0143] The cells were stimulated with 100 ng / mL LPS and treated with 25 μg / mL AD. The results showed that after 12 h of culture, AD significantly inhibited the increase in LPS-induced cell glycolysis, which was reflected by the reduction of lactic acid production. At the same time, AD significantly inhibited the LPS-induced upregulation of mRNA expression of HK2, a key enzyme in glycolysis (see Figure 4 ).

[0144] 4.5. Kauri extract (AD) inhibits LPS-induced acute lung injury in mice with sepsis

[0145] AD (100 mg / kg / day oral administration) significantly increased the survival rate of mice with sepsis induced by high-dose (45 mg / kg) LPS. AD (100 mg / kg / day oral administration) significantly reduced the increase in lung weight index of mice with sepsis induced by LPS (20 mg / kg); M1 polarized macrophage infiltration in the lung tissue, as reflected by the inhibition of increased mRNA expression levels of CD86 and CD80; and significantly inhibited the expression of inflammatory factors IL-6, TNF-α, IL-1β, and IL-18 in lung tissue, indicating that AD significantly inhibited inflammatory damage to lung tissue. HE staining results showed that AD significantly inhibited LPS-induced inflammatory cell infiltration and alveolar septal thickening in the lung tissue of mice, indicating that AD significantly inhibited LPS-induced acute lung injury in mice with sepsis (see Figure 5 ).

[0146] 4.6 Monomeric AO inhibits LPS-induced M1 polarization, inflammation, and oxidative stress in RAW 264.7 macrophages

[0147] When cells were stimulated with 100 ng / mL LPS, they were treated with 25 μM AO or 25 μg / mL AD. The results showed that AO significantly inhibited the increase in mRNA expression levels of inflammatory factors MCP-1, IL-6, and TNF-α induced by LPS; inhibited the increase in mRNA expression levels of M1 polarization marker iNOS; and 100 μM AO treatment significantly inhibited the expression of M1 polarization markers CD80 and CD86; AO inhibited the protein expression level of inflammatory factor IL-18 induced by LPS, and upregulated the protein expression level of antioxidant protein HO-1 induced by LPS (see Figure 6 ).

[0148] 4.7 Monomeric AO inhibits LPS-induced acute lung injury in mice with sepsis

[0149] AO (100 mg / kg / day, intragastrically administered) significantly reduced the increase in lung weight index of septic mice induced by LPS (20 mg / kg); reduced the infiltration of M1 polarized macrophages in the lung tissue, as reflected by the inhibition of the increase in the mRNA expression levels of CD86 and CD80; and significantly inhibited the mRNA expression levels of inflammatory factors IL-6, TNF-α, and IL-1β in the lung tissue, indicating that AO significantly inhibited the inflammatory damage of the lung tissue of septic mice induced by LPS. HE staining results showed that AO significantly inhibited the infiltration of inflammatory cells and thickening of alveolar septa in the lung tissue of septic mice induced by LPS, indicating that AO significantly inhibited the acute lung injury of septic mice induced by LPS (see Figure 7 ).

Claims

1. Use of kauri extract in the preparation of products for preventing and / or treating acute lung injury caused by sepsis.

2. The use according to claim 1, characterized in that: The septic acute lung injury is septic acute lung injury caused by bacterial infection.

3. Use of Kauri extract in at least one of the following: 1) Application in the preparation of products for inhibiting acute lung injury caused by sepsis; 2) Application in the preparation of products for inhibiting inflammatory response of lung tissue; 3) Application in the preparation of products for inhibiting macrophage M1 polarization; 4) Application in the preparation of products for inhibiting the production of macrophage inflammatory factors; 5) Application in the preparation of products for inhibiting oxidative stress of M1 polarized macrophages; 6) Application in the preparation of products for inhibiting aerobic glycolysis of M1 polarized macrophages.

4. The use according to claim 3, characterized in that: The septic acute lung injury is septic acute lung injury caused by bacterial infection; The inhibition of acute lung injury caused by sepsis is specifically reflected in the inhibition of increase in lung weight index, alveolar interstitial remodeling and inflammatory cell infiltration; The factors of lung tissue inflammation are TNF-α, IL-18, IL-6 and IL-1β; The markers of macrophage M1 polarization are CD86, CD80 and iNOS; The macrophage inflammatory factors are IL-6, MCP-1 and TNF-α; The anti-oxidative stress protein of the M1 polarized macrophages is HO-1 protein; The key enzyme for inhibiting aerobic glycolysis of M1 polarized macrophages is hexokinase 2, which is manifested by inhibiting glucose consumption and lactate production.

5. The use according to any one of claims 1 to 4, characterized in that: The active ingredient of the Kauri extract includes Araucarone (AO), and its structural formula is as follows:

6. The use according to any one of claims 1 to 4, characterized in that: The Kauri extract is an ethanol aqueous solution extract of Kauri.

7. The use according to claim 6, characterized in that: The volume fraction of ethanol in the ethanol aqueous solution is 60% to 100%.

8. The use according to any one of claims 1 to 7, characterized in that: The product is a drug or a drug preparation.

Citation Information

Patent Citations

  • The use of kauranes compounds in the manufacture of medicament for treatment of cardiac hypertropy and pulmonary hypertension

    CN108348481A

  • Application of kaura fir extract in preparation of anti-non-alcoholic fatty liver product

    CN112933120A

  • Application of kaurane compound in preparation of medicines for preventing and treating sepsis and multi-organ injury

    CN113262215A

  • Application of kaurane compound in preparation of medicine for preventing and treating inflammatory bowel disease

    CN113304133A

  • Application of cowherb seed flavonoid glycoside in preparation of medicine for treating sepsis

    CN114748493A